XRAY
Overvalued by 4.9% based on the discounted cash flow analysis.
Market cap | $5.89 Billion |
---|---|
Enterprise Value | $7.69 Billion |
Dividend Yield | $0.5726 (2.02%) |
Earnings per Share | $-0.45 |
Beta | 0.85 |
Outstanding Shares | 207,630,556 |
Avg 30 Day Volume | 3,171,291 |
Return on Equity | - |
---|---|
Return on Assets | - |
Return on Invested Capital | - |
P/E Ratio | -62.03 |
---|---|
PEG | 31.85 |
Price to Sales | 1.57 |
Price to Book Ratio | 1.89 |
Enterprise Value to Revenue | 1.95 |
Enterprise Value to EBIT | 27.77 |
Enterprise Value to Net Income | -81 |
Total Debt to Enterprise | 0.27 |
Debt to Equity | 0.64 |
No data
No data